QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
NASDAQ:AIKI

AIkido Pharma Stock Forecast, Price & News

$0.83
0.00 (-0.11 %)
(As of 10/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.80
$0.86
50-Day Range
$0.73
$0.90
52-Week Range
$0.47
$2.55
Volume2.95 million shs
Average Volume8.29 million shs
Market Capitalization$74.65 million
P/E RatioN/A
Dividend YieldN/A
Beta1.51
30 days | 90 days | 365 days | Advanced Chart
Receive AIKI News and Ratings via Email

Sign-up to receive the latest news and ratings for AIkido Pharma and its competitors with MarketBeat's FREE daily newsletter.


AIkido Pharma logo

About AIkido Pharma

AIkido Pharma, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. Its oncology therapeutics includes treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It also creates broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. The company was founded by Gilbert V. Levin and M. Karen Levin in 1967 and is headquartered in New York, NY.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AIKI
Employees
5
Year Founded
1967

Sales & Book Value

Annual Sales
$10,000.00
Book Value
$0.85 per share

Profitability

Net Income
$-12.34 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$74.65 million
Next Earnings Date
11/12/2021 (Estimated)
Optionable
Not Optionable

Social Links


MarketRank

Overall MarketRank

1.73 out of 5 stars

Medical Sector

871st out of 1,361 stocks

Commercial Physical Research Industry

15th out of 26 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












AIkido Pharma (NASDAQ:AIKI) Frequently Asked Questions

Is AIkido Pharma a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AIkido Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AIkido Pharma stock.
View analyst ratings for AIkido Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than AIkido Pharma?

Wall Street analysts have given AIkido Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AIkido Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting AIkido Pharma?

AIkido Pharma saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 678,000 shares, an increase of 43.5% from the September 15th total of 472,600 shares. Based on an average daily trading volume, of 3,130,000 shares, the short-interest ratio is currently 0.2 days. Approximately 2.0% of the company's shares are sold short.
View AIkido Pharma's Short Interest
.

When is AIkido Pharma's next earnings date?

AIkido Pharma is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.
View our earnings forecast for AIkido Pharma
.

How were AIkido Pharma's earnings last quarter?

AIkido Pharma Inc. (NASDAQ:AIKI) posted its earnings results on Wednesday, August, 11th. The business services provider reported ($0.02) EPS for the quarter.
View AIkido Pharma's earnings history
.

How has AIkido Pharma's stock price been impacted by COVID-19 (Coronavirus)?

AIkido Pharma's stock was trading at $1.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AIKI stock has decreased by 58.2% and is now trading at $0.8324.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for AIKI?

1 analysts have issued twelve-month target prices for AIkido Pharma's stock. Their forecasts range from $2.00 to $2.00. On average, they expect AIkido Pharma's share price to reach $2.00 in the next year. This suggests a possible upside of 140.3% from the stock's current price.
View analysts' price targets for AIkido Pharma
or view top-rated stocks among Wall Street analysts.

Who are AIkido Pharma's key executives?

AIkido Pharma's management team includes the following people:

What other stocks do shareholders of AIkido Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AIkido Pharma investors own include Biocept (BIOC), AIM ImmunoTech (AIM), Nuwellis (CHFS), Foresight Autonomous (FRSX), iBio (IBIO), Exela Technologies (XELA), Bionano Genomics (BNGO), Check-Cap (CHEK), Digital Ally (DGLY) and Purple Biotech (KTOV).

What is AIkido Pharma's stock symbol?

AIkido Pharma trades on the NASDAQ under the ticker symbol "AIKI."

How do I buy shares of AIkido Pharma?

Shares of AIKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AIkido Pharma's stock price today?

One share of AIKI stock can currently be purchased for approximately $0.83.

How much money does AIkido Pharma make?

AIkido Pharma has a market capitalization of $74.65 million and generates $10,000.00 in revenue each year.

How many employees does AIkido Pharma have?

AIkido Pharma employs 5 workers across the globe.

Does AIkido Pharma have any subsidiaries?

The following companies are subsidiares of AIkido Pharma: Hoth Therapeutics.

When was AIkido Pharma founded?

AIkido Pharma was founded in 1967.

What is AIkido Pharma's official website?

The official website for AIkido Pharma is www.spherix.com.

Where are AIkido Pharma's headquarters?

AIkido Pharma is headquartered at ONE ROCKEFELLER PLAZA 11TH FLOOR, NEW YORK NY, 10020.

How can I contact AIkido Pharma?

AIkido Pharma's mailing address is ONE ROCKEFELLER PLAZA 11TH FLOOR, NEW YORK NY, 10020. The business services provider can be reached via phone at (112) 745-1374 or via email at [email protected].


This page was last updated on 10/18/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.